Decorin protein core affects the global gene expression profile of the tumor microenvironment in a triple-negative orthotopic breast carcinoma xenograft model by Buraschi, Simone et al.
Decorin Protein Core Affects the Global Gene Expression
Profile of the Tumor Microenvironment in a Triple-
Negative Orthotopic Breast Carcinoma Xenograft Model
Simone Buraschi
1., Thomas Neill
1., Rick T. Owens
2, Leonardo A. Iniguez
3, George Purkins
1,
Rajanikanth Vadigepalli
1, Barry Evans
1, Liliana Schaefer
4, Stephen C. Peiper
1, Zi-Xuan Wang
1,
Renato V. Iozzo
1*
1Department of Pathology, Anatomy and Cell Biology, and the Cancer Cell Biology and Signaling Program, Kimmel Cancer Center, Thomas Jefferson University,
Philadelphia, Pennsylvania, United States of America, 2LifeCell Corporation, Branchburg, New Jersey, United States of America, 3Roche NimbleGen, Inc., Research and
Development, Madison, Wisconsin, United States of America, 4Department of Pharmacology, Goethe University, Frankfurt, Germany
Abstract
Decorin, a member of the small leucine-rich proteoglycan gene family, exists and functions wholly within the tumor
microenvironment to suppress tumorigenesis by directly targeting and antagonizing multiple receptor tyrosine kinases,
such as the EGFR and Met. This leads to potent and sustained signal attenuation, growth arrest, and angiostasis. We thus
sought to evaluate the tumoricidal benefits of systemic decorin on a triple-negative orthotopic breast carcinoma xenograft
model. To this end, we employed a novel high-density mixed expression array capable of differentiating and simultaneously
measuring gene signatures of both Mus musculus (stromal) and Homo sapiens (epithelial) tissue origins. We found that
decorin protein core modulated the differential expression of 374 genes within the stromal compartment of the tumor
xenograft. Further, our top gene ontology classes strongly suggests an unexpected and preferential role for decorin protein
core to inhibit genes necessary for immunomodulatory responses while simultaneously inducing expression of those
possessing cellular adhesion and tumor suppressive gene properties. Rigorous verification of the top scoring candidates led
to the discovery of three genes heretofore unlinked to malignant breast cancer that were reproducibly found to be induced
in several models of tumor stroma. Collectively, our data provide highly novel and unexpected stromal gene signatures as a
direct function of systemic administration of decorin protein core and reveals a fundamental basis of action for decorin to
modulate the tumor stroma as a biological mechanism for the ascribed anti-tumorigenic properties.
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Introduction
The traditional view of tumorigenesis has long been considered
in the perspective of oncogenes and tumor suppressor genes
governing diverse cellular processes such as cell proliferation,
survival, migration, and metastasis, with a prominent focus on
understanding the cellular imbalance existing among these two
populations of nuclear encoded genes. However, the importance
of the surrounding tumor environment has begun to emerge as an
active participant in orchestrating many aspects of tumor growth
and progression including invasion, metastasis, and angiogenesis
[1,2]. The heterogeneous interactions between neoplastic cells and
stromal components such as fibroblasts, tumor macrophages,
extracellular matrix, host and tumor endothelial cells as well as
basement membrane, collectively known as the tumor microen-
vironment, can have profound effects on tumorigenesis. However,
despite the importance of tumor-stroma interactions, there is a
limited understanding of its composition and how the complex
inter-relationships between growing malignant cells and stromal
constituents take place.
The stromal-specific decorin is encoded by a large and
complex gene (DCN) located on chromosome 12q23 which
contains two alternatively-spliced leader exons [3] and a quite
complex promoter region [4,5]. Notably, DCN transcriptional
activity is induced by hypomethylation of its promoter [6,7] and
by quiescence [8,9], and inhibited by TNFa [9], TGFb [10]
and viral oncogenes [11]. Decorin is a secreted small leucine-
rich proteoglycan that binds collagen I and regulates fibrillo-
genesis [12–23], and is known to bind avidly to TGFb [24] and
regulate its bioactivity [25–27]. In addition, decorin-deficient
mice are less susceptible to experimental infection by Borrelia
burgdorferi, the spirochete responsible for Lyme disease in
humans [28,29].
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downregulating several receptor tyrosine kinases (RTKs) [30] such
as the EGFR [31–34], IGF-IR [35–38], and Met [39–41]
primarily by evoking caveolin-mediated internalization and
degradation [31,39,42]. This leads to mobilization of intracellular
calcium [43], concurrent induction of cyclin-dependent kinase
inhibitor p21
WAF1 [44,45] and subsequent degradation of key
downstream effectors such as b-catenin and Myc in various tumor
xenografts [40].
Under growth conditions, b-catenin and Myc are stabilized by
activation of Wnt and various RTK signaling pathways, which are
often hyperactive in cancer. Thus, upstream activation of these
signaling pathways leads to inactivating phosphorylation of GSK-
3b by PI3K/Akt to allow for translocation of active b-catenin and
Myc into the nucleus where, through association with various
nuclear co-activator complexes, enable induction of a large
number of genes including Myc itself [46,47], and AP4, a
transcriptional repressor of p21 [48]. In contrast, decorin, by
neutralizing the activity of EGFR and Met, relieves GSK3b
inactivation, and leads to non-canonical GSK3b-evoked phos-
phorylation of b-catenin as well as Myc at Thr58 [39,40], thus
leading to 26S proteasomal degradation. Thereby, the synthesis of
AP4 would cease and p21 would be released from Myc/AP4-
mediated transcriptional repression, as a direct biological mani-
festation of decorin-evoked suppression of RTK activity and
tumorigenic growth [49]. Moreover, the relevance of decorin in
cancer progression has been demonstrated in mutant mice where
,30% of decorin-null mice develop spontaneous intestinal tumors
[50], whereas decorin-null mice carrying a targeted disruption in
p53 succumb within 3–4 months to aggressive lymphomas [51].
Decorin is also involved in the regulation of angiogenesis
[52,53] and blocks tumor cell-mediated angiogenesis by downreg-
ulating VEGFA production [54], as well as Met and downstream
angiogenic networks [55]. Moreover, recombinant decorin pro-
teoglycan or decorin protein core inhibits metastatic spreading of
breast carcinoma xenografts [56,57]. Adenoviral-mediated dec-
orin gene delivery and/or via systemic treatment retards the
growth of various tumor xenografts including squamous, breast,
and prostate carcinomas [32,42,56–62]. Low levels of decorin are
present in invasive breast carcinomas [63] and this trait is
associated with poor outcome in breast [64] and lung cancer
patients [65]. Moreover, abnormal decorin expression has been
detected in mammographic density [66], a major risk factor for
breast cancer [67–69], and array data have demonstrated decorin
upregulation during mammary gland involution, likely contribut-
ing to increased collagenization [70]. Thus, the expression and/or
activity of decorin could affect breast cancer risk. Accordingly, any
mechanism that would boost endogenous expression of decorin
[71] or any therapeutic modality that could efficiently and
specifically deliver decorin to carcinomas could represent a novel
therapeutic choice against cancer [72,73].
Thus, we wished to deepen our molecular understanding of its
potential role in modulating the tumor stroma by directly
investigating, at high resolution, the gene expression signature of
a triple negative breast carcinoma microenvironment. Therefore,
for the first time, we were able to dissect the complex inter-
relationship present between the tumor and the stroma by utilizing
a novel high-density microarray platform capable of simulta-
neously measuring expressed transcripts derived from both the
mouse (i.e. the stroma) and the neoplasm (i.e. the human tumor
cell line, MDA-MB-231) via interrogation of orthotopic tumor
xenografts treated systemically with decorin.
In this study, we report the stromal gene expression signature
obtained with systemic delivery of decorin protein core and
discover a total of 374 genes, which showed differential expression
profiles. Further, and unexpectedly, we found by DAVID gene
ontology analysis, a predominant inhibition of inflammatory and
immune response genes with concurrent induction of various
tumor suppressors and cellular adhesion molecules. Moreover,
independent verification of the top 12 genes demonstrating .2-
fold up or down regulatory changes identified Mrgpra2, Siglech, Irg1
and Il1b to be potently suppressed concurrent with Zc3hav1, Peg3,
and Bmp2k induction. These data posit for decorin protein core as
a potent tumor repressor by attenuating inflammation and
metastasis, which constitute several hallmarks of cancer.
Results
MDA-231(GFP+) Tumor Xenografts Respond to Systemic
Delivery of Decorin
We performed experiments utilizing a very aggressive MDA-
231(GFP+) triple-negative breast carcinoma cell line. We discov-
ered that decorin evoked growth inhibition in vitro, enhanced
apoptosis and blocked EGF- and FGF-mediated evasion from
Matrigel (not shown), indicating that decorin exerts similar
inhibitory activity on EGFR and Met dependent pathways as
shown for other carcinoma cells [39,40,42,57]. Subsequently, we
injected ,3 million MDA-231(GFP+) cells into the mammary fat
pads of SCID mice (n=6 each), and when the tumor reached
palpable size we treated them with daily i.p. injections of
recombinant decorin protein core (10 mg/Kg). Purity of the
preparation of decorin protein core was established by SDS
polyacrylamide gel electrophoresis followed by staining with
Colloidal Coomassie blue which can detect as little as 5 ng of
protein. We did not find any co-purifying contaminants using this
method (Figure S1). Therefore, based on this information, and
since the largest amount of decorin protein core loaded was 5 mg,
our preparation of decorin protein core is .99% pure. The results
show that decorin protein core (henceforth designated decorin)
was capable of retarding the growth of the breast carcinoma
xenografts (Figure 1A–D), which was highly significant at day 23
(Figure 1B, P,0.001). At the end of the experiments, the tumors
were snap-frozen in liquid nitrogen and RNA was extracted for
NimbleGen analysis.
Analysis of Stromal (Mus Musculus) and Epithelial (Homo
Sapiens) mRNA by the NimbleGen High-Density Mixed
Expression Array Platform
To achieve a greater understanding of the governing interac-
tions between the neoplastic cells and surrounding microenviron-
ment we initially investigated the transcriptome of breast cancer
stroma utilizing the orthotopic human mammary carcinoma
xenografts described above. This approach is based on the
utilization of a unique high-density microarray platform capable of
differentiating and profiling transcripts from both human and
mouse origin on the same array (NimbleGen 36720 K). The
mixed gene expression chip allows three arrays per slide with each
array exhibiting 720,000 probes representative of transcripts
originating from both human neoplastic cells and mouse stroma
components. Appropriate sample labeling of the validated cDNA
was followed by hybridization to the 36720 K array followed by
scanning using the Roche NimbleScan software, which normalizes
the expression data using quantile normalization as determined by
the Robust Multichip Average algorithm. Expression data were
tested for significance using a mixed effects model ANOVA in R.
Genes were sorted by P-value, and then by fold change. Genes
with P,0.05 were placed into upregulated and downregulated
groups as illustrated with the resultant heat maps. We have
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available GEO System with accession number GSE37937. Global
expression profiles comparing human breast carcinoma in decorin
treated when compared to vehicle control showed that most of the
genes in two independent experiments (n=6 each) showed close
grouping with only minor changes (Figure 2A). Indeed, we found
no significant (P,0.05) changes in any of the human-derived
genes. In contrast, the number of genes derived from the tumor
stroma of decorin-treated animals showed significant changes,
with both upregulated and downregulated genes (Figure 2B). To
further refine the search, we performed Principal Component
Analysis and eliminated two outliers from each group. With this
filtered set (n=4 each), we identified 374 differentially expressed
genes with P,0.05. Among all the genes, we selected the top 27
genes exhibiting greater than 2-fold down or upregulation and
P,0.01. Notably, these genes clustered very well (Figure 2C).
These findings show that systemic delivery of decorin in this
triple-negative orthotopic breast carcinoma xenograft predomi-
nantly affects the global gene signature of the tumor microenvi-
ronment.
Stromal Decorin Differentially Inhibits Expression of
Immunomodulatory Genes and Concomitantly Induces
Expression of Mutliple Tumor Suppressor Genes
Gene ontology (GO) analysis was performed on the microarray
data set comprising the 374 differentially expressed genes
exhibiting P,0.05. Utilization of the Database for Annotation,
Visualization, and Integrated Discovery (DAVID v6.7) [74]
allowed for a detailed ontology analysis based on the assigned
cellular and molecular functions of the differentially regulated
stromal genes in the presence of decorin. We thereby found the
genes clustering into 5 discrete downregulated and 6 upregulated
GO terms (Figure 3), associating with high significance values.
Remarkably, the leukocyte chemotactic and inflammatory genes
represented the most significantly downregulated class (n=63,
enrichment score of 3.35, P=0.0014) among the differentially
regulated stromal genes followed by contractile fiber genes and
those responsible for orchestrating the general immune response
(Figure 3). This representation of GO terms is appropriate and
consistent as the most downregulated gene (25.3 folds), as
determined by microarray analysis (cfr. Figure 2C), was immune
response gene 1 (Irg1). Interestingly, full expression of Irg1 is
dependent on estrogen signaling [75] and is a gene typically
induced in macrophages by pro-inflammatory stimuli such as TLR
agonists (lipopolysaccharide), IFNc, and TNFa [76,77]. It is
important to note that our MDA-231 orthotopic breast carcinoma
models used for these studies are triple negative for ERa/PgR/
HER2. Thus, these findings indicate an estrogen-independent
mode of Irg1 downregulation via decorin. Importantly, and to the
best of our knowledge, this gene has not previously been
implicated in breast tissue and/or tumor progression and may
serve as a novel component in tumorigenesis and detection.
Other suppressed immunomodulatory genes of interest included
Siglech (Sialic acid binding Ig-like lectin; 22.3 folds, P=0.00844),
Lipg (IFNc inducible GTPase; 22.72 folds, P=0.0082), and Il1b
(Interleukin 1b; 22.3 fold, P=0.0046). Siglech is a member of the
Ig gene superfamily, which binds avidly to sugars and is the mouse
homologue of SIGLEC-15, the only known family member to
maintain complete conservation throughout vertebrate evolution
[78]. Lipg is a member of the small GTPase family of Golgi- and
endoplasmic reticulum-associated subfamily activated primarily by
TLR signaling and IFNc [79–81]. Finally, Il-1b is a primary
mediator of innate and adaptive immune responses and has been
firmly established as a regulator of cancer progression via control
of proliferation and apoptotic processes [82].
Taken together, this signature of decorin-suppressed stromal
genes indicates an immunosuppressive nature and constitutes a
very poorly understood and under-investigated area of decorin
bioactivity. However, recent publications are now positing a
potent immunomodulatory role for decorin in various settings
[83,84] and in tumorigenesis [85].
As for the stromal induced gene subsets, cell adhesion molecules
commanded the majority as the most significantly enriched GO
term (n=282, enrichment score of 8.73, P=0.00005) followed by
cytoskeletal components (n=113, enrichment score of 2.78,
P=0.0032), and cell cycle regulatory genes (n=107, enrichment
score of 1.88, P=0.0036) (Figure 3). The cellular and molecular
functions these gene subsets represent are highly consistent for the
ascribed properties of decorin functioning in a tumor repressive
capacity as these classifications are associated with tumor
suppressive activity.
The top stromal upregulated gene was a kinase induced by
Bmp2, known as Bmp2 inducible kinase (Bmp2k). Bmp2k is a
largely unknown and poorly investigated nuclear-localized serine/
threonine kinase that represents another candidate gene not yet
implicated in human breast cancer and might represent an
important target for decorin bioactivity as well as a potentially
novel biomarker for tumor progression.
Another decorin-induced stromal gene was cell adhesion
molecule 1 (Cadm1, 22.7 fold, P=0.0011), a transmembrane
Figure 1. Systemic delivery of decorin protein core inhibits the growth of orthotopic breast carcinoma xenografts. A: Growth of MDA-
231(GFP+) xenografts following daily i.p. injections of either PBS (black circle, control) or recombinant decorin protein core (red circle, 10 mg/kg). B:
Tumor volumes at day 23, ***P,0.001. C: Representative macroscopic photographs of control and decorin-treated animals at day 23. D:
Bioluminescence superimposed on x-ray analysis of a representative control and decorin treated animal at day 23. Images were captured with a
Kodak In-Vivo Multispectral Imaging System FX.
doi:10.1371/journal.pone.0045559.g001
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[86], also known as Tumor Suppressor in Lung Cancer (TSLC1).
Expression of Cadm1 is lost in various malignancies, including
breast [87], due to promoter hypermethylation.
An additional decorin-induced target classified as a tumor
suppressor gene within the stroma, was Peg3 (paternally expressed
gene 3, 2.49-folds, P=0.0078) and it encodes a zinc finger
transcription factor (Cys2His2 variety) of the Kru ¨pple-type family.
Similarly to Cadm1, this gene is also frequently silenced by
promoter hypermethylation and/or loss of heterozygosity in
several tumors including ovarian cancer [88] and gliomas [89].
The results derived from the DAVID gene ontology analysis
provided a critical assignment of cellular and molecular function to
our data subsets that are largely consistent with the top scoring
genes as determined by the mixed microarray. These data suggest
a novel role for decorin as a key immunosuppressive agent that is
acting on the tumor stroma that may compromise the tumor-
immune system interface, which is crucial for maintaining
continued tumor progression. Simultaneously, decorin induces
the expression of several tumor suppressor genes that, like several
of the downregulated targets, have never previously been linked to
cancer progression.
Validation of Differentially-expressed Stromal Genes by
Systemic Decorin Delivery
Independent verification of microarray datasets is absolutely
critical for determining the validity and biological fitness of the
presumed findings. Since the microarray platform was unique
insofar as containing probes representing two different species and
our data report the impact of decorin on stromal gene signatures
(of Mus musculus origin) we therefore designed primers using the
Universal Probe Library (Table S1) that are specific only for M.
musculus transcripts, aimed at the top 6 up- and down-regulated
(exhibiting P,0.01) stromal genes. Thereby, we have rigorously
authenticated our primers in both M. musculus cDNA, harvested
from NIH3T3 cells (positive control), and Homo sapiens cDNA as
derived from HeLa cells (negative control for primer specificity).
Our primers were capable of differentiating and recognizing only
M. musculus mRNA species, in contrast to H. sapiens mRNA as
validated by qPCR under identical thermal cycling conditions
Figure 2. Systemic delivery of decorin protein core alters the gene expression profile of the mammary tumor stroma xenografts.
A,B: Global expression profile comparing log2 expression of vehicle control vs. decorin-treated tumor xenograft samples. Notice that the effects of
decorin are more pronounced in the gene expression profile of the mouse-derived tumor stroma. C: Hierarchical clustering of the top 36 genes
downregulated (n=12) or upregulated (n=15) in the mouse tumor stroma in control and decorin-treated mice. These 27 top genes were selected on
the basis of two criteria: .2-fold change and P,0.01.
doi:10.1371/journal.pone.0045559.g002
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discernable amplification in H. sapiens when compared to
M. musculus where a majority of the primer sets reported signal
in the early to mid-range of thermal cycle 20. Thus, these data
indicate high sensitivity with exquisite recognition and specificity
for only M. musculus transcripts.
Utilizing mRNA extracted from the same tumor xenografts
(systemic decorin treatment for 23 days at 10 mg/Kg) and that
used for the microarray experiments, we performed qPCR as a
method to validate stromal gene expression for Mrgpra2, Gucy1a3,
Siglech, Ligp, Irg1, and Il1b (downregulated genes) and for Bmp2k,
Cadm1, Hey1, Peg3, Brd4, Zc3hav1 (upregulated genes). We were
able to recapitulate and confirm the gene expression signatures for
four (,67%) of the downregulated genes (Mrgpra2, Siglech, Irg1, and
Il1b; P,0.001) and for three (50%) of the upregulated genes
(Zc3hav1, Peg3, and Bmp2k; P,0.001) (Figure 4). The remaining
genes (Cadm1, Hey1, Brd4, Gucy1a3, and Ligp) could not be faithfully
reproduced due primarily to unfavorably high thermal cycle value
Figure 3. DAVID gene ontology analysis. Rigorous classification of the 374 differentially expressed genes within the tumor microenvironment of
triple negative breast carcinoma xenografts following systemic treatment with decorin protein core for 23 days. Determinations for the down- and
upregulated classes were selected on highly stringent criteria (P,0.05). Thus, all subsets above this value were analyzed by summing all genes within
a specific gene ontology class followed by deriving the mean P and Benjamini values.
doi:10.1371/journal.pone.0045559.g003
Table 1. Demonstration that qPCR verification primers exhibit exquisite specificity for NIH3T3 (mouse embryonic fibroblasts)
cDNA when directly compared to HeLa (human squamous cell carcinoma) cDNA.
Official Gene Symbol HeLa cDNA Average Ct (± S.D.) NIH3T3 cDNA Average Ct (± S.D.) Average DCt (HeLa – NIH3T3 Ct)
Bmp2k 32.92 (60.18) 26.03 (60.16) 6.89
Mrgpra2 36.57 (60.36) 28.28 (60.38) 8.29
Cadm1 Not Detected 37.40 (60.16) N/A
Hey1 Not Detected 31.52 (60.49) N/A
Gucy1a3 35.88 (60.70) 28.33 (60.27) 7.55
Peg3 Not Detected 25.41 (60.17) N/A
Brd4 37.25 (60.33) 22.58 (60.02) 14.67
Zc3hav1 Not Detected 25.36 (60.20) N/A
Siglech Not Detected 29.67 (60.12) N/A
Ligp Not Detected 33.17 (60.14) N/A
Irg1 Not Detected 34.83 (64.26) N/A
Il1b Not Detected 26.49 (61.00) N/A
Average Ct (6 S.D.) values were obtained via qPCR for each gene primer set listed above when exposed to either NIH3T3 or HeLa template cDNA following standard 40
cycle SYBR Green evaluation as performed on the Roche 480 LightCycler II platform in either quadruplicate (HeLa) or triplicate (NIH3T3). HeLa Ct values scored as ‘‘Not
Detected’’ refers to either all four replicates failing to register a detectable amplicon threshold or reflects that only one replicate achieved threshold detection, which
most likely reflects stochastic amplicon formation at higher Ct values (.35); further, values that surpassed a Ct of 35 were considered as ‘‘Not Detected’’.
doi:10.1371/journal.pone.0045559.t001
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employed, suggesting low transcript number.
These data suggest a modulation of immunological genes,
consistent with the aforementioned DAVID gene ontology
analysis. Importantly, we demonstrate a reproducible induction
of a presumed tumor suppressor gene (Peg3) within the stromal
compartment as well as implicating a novel role for Bmp2k in
breast cancer samples.
Co-Cultures Mimic Decorin Regulated Stromal Genes In
Vitro
We hypothesized that establishment of a co-culture approach
could reconstitute in part the decorin-evoked in vivo stromal gene
expression signatures obtained from the tumor xenografts in an in
vitro setting. Thus, we utilized primary cell isolates of mouse
mammary fibroblasts of the same genetic background (C57BL/6J)
as the host for the tumor xenografts and added human mammary
carcinoma MDA-231 cells to this feeder layer of primary
mammary fibroblasts. Once attached, co-cultures were serum
starved for 24 hours followed by chronic treatment with decorin
(100 nM) for 3 days whereupon RNA was harvested and prepared
as a mixed cDNA population. We focused on the expression
pattern of the seven previously verified genes as reported above.
Analysis of these stromal genes in context of the co-culture via
qPCR revealed a recapitulation of the expression patterns of Peg3,
Bmp2k, and Zc3hav1 (Figure 5; P,0.001), the same stromal genes
verified as induced by decorin within the tumor xenografts.
However, the extents of induction among these genes were not as
dramatic as shown for the verification in vivo (cfr. Figure 4). This
reflects several possibilities such as the length of decorin treatment,
differences in nutrient obtainment via the blood vessels and/or the
lack of additional stromal cells (endothelial cells and inflammatory
cells), which might synergize and ultimately prove necessary for
more robust decorin-mediated induction.
It is of note to mention that expression patterns of the
immunomodulatory genes could not be reconstituted since our
cultures lacked immune system components and/or fibroblasts
that do not normally express these genes. Finally, and although
Siglech was highly detectable within our co-culture system, we
found no significant change of its expression (Figure 5; P.0.05).
Collectively, these findings indicate that decorin is capable of
targeting the tumor stroma in addition to the well-established anti-
oncogenic activity targeting the carcinoma cells.
Decorin Induces Peg3, Bmp2k and Zc3hav1 in a Co-
culture and Tumor Xenografts
Following extensive qPCR analyses, we next sought to
determine the levels of Peg3 and Bmp2k in a co-culture of mouse
mammary fibroblasts and MDA-231 that were exposed to either
vehicle (control) or decorin (200 nM) for up to 3 days. We found a
marked increase of both Peg3 and Bmp2k expression in treated
cells compared to controls as detected by immunoblot (Figure 6).
To further strengthen the in vivo relevance of our data, we
determined the expression of Peg3 and Bmp2k in the same
Figure 4. Independent qPCR verification of NimbleGen targets
in orthotopic MDA-231 tumor xenografts following systemic
delivery of human recombinant decorin protein core. Of the 36
top scoring candidates, we selected the top six-upregulated and
downregulated targets and verified the corresponding expression
patterns independently via real time quantitative PCR (qPCR) analysis
on the same MDA-231 tumor xenograft total RNA utilized for the
NimbleGen Mixed expression array. Since these 12 candidate genes
represent differential stromal (mouse) gene expression signatures, we
ensured our primers exhibit extreme stringency and specificity for only
Mus musculus transcripts (cfr. Table 1). Therefore, we were able to
demonstrate reproducibility and verification for seven of the twelve
candidate genes, representing four downregulated (Mrgpra2, Siglech,
Irg1, Il1b) and three upregulated (Zc3hav1, Peg3, Bmp2k) transcripts in
our MDA-231 xenograft mouse model. Data are representative of three
independent samples for each sample cohort in quadruplicate
replicates, analyzed with the DDCt method (please see Materials and
Methods for a more detailed explanation), and reported as the average
fold change 6 SEM (***P,0.001).
doi:10.1371/journal.pone.0045559.g004
Figure 5. Co-Culture Gene Expression Analysis of NimbleGen
Targets. Co-culture conditions were established by utilizing and
plating primary mouse mammary fibroblasts followed, once at sub-
confluency, by the addition of ,10
5 MDA-231 cells. Co-cultures were
then serum starved for a 24 h period prior to exposure of 100 nM
decorin protein core for a total 3–4 days under serum free conditions.
Gene expression analysis was carried out via qPCR by employing the
same Mus musculus specific primers as in the preceding section for
seven of the target genes, as were reproduced in Figure 4. Recapitu-
lation of the in vivo gene signature involved reproducible patterns for
four of the genes (Peg3, Bmp2K, and Zc3hav1). Data are representative
of two independent trials performed in triplicate. Fold changes reflect
two independent trials employing quadruplicate replicates and
analyzed with the DDCt method (Please refer to Materials and Methods)
and reported as the average 6 SEM (***P,0.001).
doi:10.1371/journal.pone.0045559.g005
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treatment with decorin resulted in an induction of Peg3 (Figure 7A)
as well as Bmp2k (Figure 7B) and Zc3hav1 (Figure S2) within the
tumor stroma as visualized via immunofluorescence and quanti-
fied using three-dimensional surface plots of the fluorescent signal.
Thus, these in vivo data provides further proof that decorin
significantly affects the tumor microenvironment via induction of
Peg3, Bmp2k and Zc3hav1 at the protein and transcriptional
levels as suggested by the mixed microarray data.
Invasive Ductal Breast Carcinoma Microarray Datasets
Show a Clear Reduction in PEG3
Next, we analyzed PEG3 expression in different publically
available breast cancer microarray datasets using the ONCO-
MINE database and gene microarray data analysis tool [90]. This
database was specified to query individual published microarray
analyses as well as to produce a summary statistic across each
distinctive gene expression study for PEG3 mRNA levels detected
in various ductal breast carcinoma samples. Two independent
studies [91,92] demonstrated a statistically significant decrease
(Figure 8) of PEG3 mRNA expression when compared to normal,
non-neoplastic controls. Precisely, the dataset by Karnoub et al.
reported a 3.1-fold decrease (P=3.6610
26)o fPEG3 mRNA
within invasive ductal breast carcinoma (Figure 8, left panel) which
is consistent with a study by Richardson et al, where a 5.6-fold
reduction (P=1.86610
26)o fPEG3 expression was found in ductal
breast carcinoma (Figure 8, right panel). No data were available in
the ONCOMINE for either BMP2K or ZC3HAV1 related to breast
cancer.
These data provide further in vivo validation concerning the
clinical relevance and potentially critical role of PEG3,
functioning as a tumor suppressor, in the progression of
aggressive ductal breast carcinomas. Moreover, these studies
provide strong rationale for the novel induction of PEG3 within
this malignancy by decorin as a possible mechanism of
inhibiting tumorigenesis.
Discussion
A current prevailing view is that tumor-associated stroma is
activated by cancer cells to foster tumor growth by secreting
growth factors, enhancing angiogenesis, and facilitating cell
migration, ultimately culminating in metastasis to remote organ
sites [93–97]. Thus, genes mediating tumor-stroma interactions
could provide novel targets for diagnostic development and
therapeutic intervention [98]. Exploratory genome-wide analysis
of the tumor microenvironment in breast cancer has been limited
to date. Using serial analysis of gene expression coupled with
antibody-based ex vivo tissue fractionation, Polyak and co-workers
identified 417 cell-type-specific genes among the most prominent
cell types in breast cancer [97]. They demonstrated gene
expression alterations in all cell types within the tumor microen-
vironment accompanying progression from normal breast tissue to
ductal carcinoma in situ (DCIS) to invasive ducal carcinoma (IDC),
providing evidence that these cell types all participate in
tumorigenesis. Park and colleagues more recently obtained gene
expression profiles of both epithelial and stromal compartments
from the same tumor biopsy using laser capture microdissection
(LCM) and described a stromal gene expression profile capable of
predicting clinical outcome [99]. Further, using LCM, Sgroi and
colleagues discovered that most of the gene expression changes
take place prior to local invasion and, surprisingly, no major
changes in gene expression accompanying the in situ-to-invasive
growth transition [100].
Similarly, analysis of the tumor microenvironment by the same
authors revealed, in analogy to the epithelium, that the tumor
stroma undergoes extensive gene expression alterations even at the
pre-invasive stage of DCIS, supporting the view that paracrine
mechanisms play an important role [101]. The observed gene
expression changes in the stroma associated with DCIS and IDC
suggests coevolution of the tumor stroma with the tumor
epithelium prior to tumor invasion.
The anti-tumorigenic properties of decorin have been presented
as a stromally derived tumor repressor that functions by directly
binding to receptor tyrosine kinases situated on the tumor cell
membrane [73]. Recently it has been shown that this mechanism
allows decorin to target potent oncoproteins such as b-catenin and
Myc for degradation while presumably rendering large genetic
networks that would otherwise favor continued tumorigenic
growth, vulnerable to changes in gene expression signatures that
would foster a less malignant state [49]. Analogously, and since
decorin is a putative matrix constituent and functions as a soluble
paracrine factor on the tumor proper, we sought to identify gene
network changes within the broader context of the tumor
microenvironment, as this compartment co-evolves with the
tumor, following systemic decorin treatment on triple-negative
orthotopic breast carcinoma xenograft to gain a better under-
standing of the molecular interplay evoked by decorin.
We found that soluble decorin protein core, acting in a
paracrine capacity, is capable of substantially altering the stromal
gene signature as evidenced by the differential modulation of 374
stromal genes. Gene ontology analysis revealed unexpected
enrichments for suppressed genes constituting immune responses
while concomitantly inducing cell adhesion and tumor suppressor
genes.
Subsequently, the array yielded reproducible signatures for
Mrgpra2, Siglech, Irg1, and Il1b (downregulated subset) and Peg3,
Bmp2k, and Zc3hav1 (induced subset). Establishment of co-cultures
(primary mouse mammary fibroblasts and MDA-231 cells) allowed
recapitulation of the mRNA expression pattern of the upregulated
genes only; our co-culture models lacked immune-competent cells,
thus the downregulated subset was not detected. Seemingly, our
data presented above seem to contradict a recently published
article indicating that decorin advocates for a more pro-
inflammatory tumor microenvironment [85]. Only intact decorin
Figure 6. Peg3 and Bmp2 expression is induced by decorin
protein core in co-cultures of MDA-231 cells and mouse
mammary fibroblasts. Representative immunoblots of MDA-231
cells and mouse mammary fibroblasts in co-culture exposed to 200 nM
decorin as indicated. Cell lysates were separated via SDS-PAGE and
immunoblotted using an anti-Peg3 or Bmp2k primary antibodies. The
bottom panels represent Coomassie Blue staining of the lower portion
of the gel. The blots are representative of three independent
experiments. Proteins were visualized with IR-Dye-labeled secondary
antibodies and quantified using Odyssey Infrared Imaging system (LI-
COR).
doi:10.1371/journal.pone.0045559.g006
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TNFa or IL-12p70 from macrophages [85]. The binding of
decorin protein core to TLR2/4 is not sufficient to evoke
downstream signaling events, which is in contract to decorin
proteoglycan. Therefore, since our present study utilized decorin
protein core, the results obtained are compatible and do not
contradict. Importantly, the mRNA data for Peg3, Bmp2k, and
Zc3hav1 were independently corroborated via immunofluorescence
and immunoblotting in not only tumor xenografts but also in co-
culture conditions, respectively, and revealed, for the first time, a
novel role for Peg3, Bmp2k, and Zc3hav1 in breast cancer
progression.
Peg3 represents a unique and distinctive class among the
repertoire of inherited genes by virtue of its genomically imprinted
status, where in this case, the paternal allele is exclusively
responsible for expressing a molecule which harbors 12 Kru ¨p-
pel-type zinc finger domains with two proline-rich periodic repeat
domains, and is frequently rendered inactive in several malignan-
cies [88,89]. Consistent with a potential role as a tumor suppressor
and in line with recent publications from our lab, it has been
experimentally shown [102] that the N-terminal SCAN domain of
Peg3 mediated direct binding to b-catenin and promotes 26S
proteasomal degradation that is, surprisingly, independent of
GSK3b. These studies phenocopy the pathway utilized by decorin
Figure 7. Systemic administration of decorin protein core induces Peg3 and Bmp2k levels in MDA-231(GFP+) xenografts. A–B:
Immunofluorescence images of control and decorin-treated MDA-231(GFP+) tumor xenografts, reacted with anti-Peg3 (A) or anti-Bmp2k (B)
antibodies. Mice bearing MDA-231(GFP+) tumor xenografts were treated with intraperitoneal injection of decorin protein core (10 mg/kg) every other
day for 23 days. All the micrographs were taken using the same exposure and gain. Three-dimensional surface plots, on the right of each panel, were
generated utilizing ImageJ software and represent Peg3 and Bmp2k expression which directly corresponds to the signal intensity obtained by the
immunofluorescence. The scale bars for signal intensity are included on the right of each surface plot. Bar=20 mm.
doi:10.1371/journal.pone.0045559.g007
Figure 8. Expression array analysis of several ductal breast carcinoma microarray datasets. Statistical significance is reported as a
summary statistic calculated utilizing the ONCOMINE gene expression tool [90]. As shown in the report by Karnoub et al. [91] (left panel) there was a
3.1-fold reduction of PEG3 mRNA within invasive ductal breast carcinoma (P=3.64610
26). Additionally, in the study by Richardson et al. [92] (right
panel), PEG3 levels were found to be decreased by 5.6-fold in ductal breast carcinoma samples (P=1.86610
26).
doi:10.1371/journal.pone.0045559.g008
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cessation of b-catenin signaling [40] and could provide a vital
link between attenuation of RTK signaling and non-canonical b-
catenin antagonism. Additionally, Peg3 has been shown to interact
with and modulate the Bax/p53 axis, in concert with the TNFa
and Wnt-related pathways as a mechanism to promote apoptosis
[103].
Our second candidate gene is Bmp2k, a poorly understood
serine/threonine kinase that plays a role in skeletal development
where activation of Bmp2k is able to attenuate osteocalcin
expression concomitant with reduced osteoblast differentiation
[104]. Intriguingly, Bmp2k has a glutamine-rich region that shares
homology to the trans-activation domain common to many
transcription factors [104]. FoxC1, a transcription factor belong-
ing to the forkhead superfamily, is subsequently able to induce the
expression of Bmp2k [105]. In a separate pathological setting, a
BMP2K variant, was reported to be strongly correlated with the
development of high myopia [106].
Lastly, we were able to confirm induction of Zc3hav1 (also
known as ZAP for zinc-finger antiviral protein), a gene hypoth-
esized to encode CCCH-type zinc finger that is largely thought to
prevent viral infection by retroviruses [107], particularly that
triggered by HIV-1 [108]. This has novel implications on the
postulated effector functions of Zc3hav1, in response to decorin, as
it comprises a link to modulate innate cellular defenses against
viral infections, and/or a mechanism to regulate endogenous RNA
signaling within the tumor microenvironment.
Moreover, the data obtained from our co-culture suggests a
potent modulatory effect on cancer-associated fibroblasts that will
have a broad impact on tumor progression. Therefore, the
changes in differential expression, as reported above, reflect gene
signatures operative within the tumor microenvironment and thus
makes assessing whether or not these changes are the result of
direct effects on the tumor proper difficult. Thus, excluding the
possibility of decorin protein core signaling via the fibroblast a2b1
integrin receptor, it is plausible that decorin is targeting the tumor
cells directly by suppressing EGFR and Met signaling (or is
integrated over several receptors), and thereby functions as a
paracrine agent to elicit changes within the surrounding tumor
stroma. However, this model cannot exclude decorin binding
directly to receptor tyrosine kinases within the stroma (such as
receptors present on endothelial cells). Importantly, we have
reported that decorin severely inhibits Myc function through
targeted proteasomal degradation [40] which, in turn, could have
stern consequences for the tumor stroma as a favorably pro-
tumorigenic environment as Myc is required for the expression of
stromal genes [109]. As an alternative possibility, it would be
possible through the established role of decorin in sequestering and
thus indirectly inhibiting the activity of TGFb, to elicit the
immunomodulatory changes in this manner [110].
In conclusion, validation of the mixed microarray data as it
pertains to stromal gene changes via several experimental
methodologies performed in vitro and in vivo revealed and
confirmed a novel involvement for Peg3, Bmp2k, and Zc3hav1,
for the first time, in breast carcinomas where, future studies may
reveal direct functions related to modulating the surrounding
tumor environment as dictated by decorin. These findings provide
a new paradigm for decorin protein core in controlling the tumor
microenvironment as a fundamental biological mechanism with
great implications for curbing tumorigenic growth by the
induction of novel tumor suppressor genes within the stroma
and for the discovery of novel gene signatures that could
eventually help clinical assessment and prognosis.
Materials and Methods
Ethics Statement
All animal studies were approved by the Institutional Review
Board of Thomas Jefferson University. At the end of each
experiment, mice were anesthetized with isoflurane and eutha-
nized with CO2 in accordance with institutional guidelines.
(Approved Protocol # 196 G).
Cells and Materials
MDA-MB-231 triple-negative breast carcinoma cells were
obtained from American Type Culture Collection (Manassas,
VA). MDA-231(GFP+) were previously described [111]. Cells
were maintained in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal bovine serum (FBS) (SAFC Biosciences,
Lenexa, KS) as well as with 100 mg/ml of penicillin/streptomycin
(MediaTech, Manassas, VA). Primary antibody against Peg3
(ab99252) was from Abcam Inc. (Cambridge, MA); anti-Bmp2k
polyclonal antibody (PA5-11724) was from Thermo Scientific
(Rockford, IL); anti-Zc3hav1 polyclonal antibody was from
Abgent (San Diego, CA).
Purification of Decorin Protein Core
Decorin protein core was purified as described elsewhere [56].
Briefly, recombinant human decorin was expressed in 293-EBNA
cells as a fusion protein to poly-His6 within a Celligen Plus
bioreactor [17]. The 293-EBNA cells were subsequently serum
starved for several days in order to maximize the output of decorin
in the media prior to purification. Under these conditions, the 293-
EBNA cells will produce both the glycanated and unglycanated
form of the recombinant decorin protein. Exploiting this method,
it was possible to purify both the proteoglycan and protein core on
an Ni-NTA chelating column followed by elution in increasing
concentrations of imidazole (0 to 250 mM) in 20 mM Tris-HCl,
500 mM NaCl, 0.2% CHAPS, pH 8.0. Finally, the proteoglycan
and core protein were separated via anion-exchange chromatog-
raphy performed on Q-Sepharose and the expected doublet of
decorin protein core was seen migrating with a molecular mass of
,50 kDa [112]. Additional evidence concerning the purity of the
decorin protein core preparation used was provided via an SDS-
PAGE gel to analyze increasing amounts (0.5, 1, 2, and 5 mg) of
decorin protein core in parallel with increasing amounts of bovine
serum albumin (BSA) (2 and 5 mg). This was followed by staining
the resultant gel with colloidal Coomassie blue (EZBlue
TM Gel
Staining Reagent, Sigma-Aldrich), which has a detection threshold
of as little as 5 ng of total protein.
Generation of Tumor Xenografts
All the animal studies performed were approved by the
Institutional Review Board of Thomas Jefferson University.
Twelve severe-combined immunodeficient (SCID) hairless female
mice (Charles River Lab., Malvern, PA) were injected with 2610
6
MDA-231(GFP+) cells into the upper left mammary fat pad. Two
weeks later, once tumors were established, mice were randomized
into two groups. Half the mice received a daily intraperitoneal
injection of recombinant protein core (10 mg/Kg). The controls
received 100 ml of PBS. Three independent experiments were
performed. Tumor growth was measured every day with a micro-
caliper according to the following formula: V=a(b
2/2), where a
and b represent the larger and smaller diameters of the tumor,
respectively. At the end of the experiment (day 23) mice were
taken to the Small Animal Imaging Facility of Thomas Jefferson
University and in vivo expression of GFP within the xenografts was
analyzed with a Kodak In-Vivo Multispectral Imaging System FX.
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dissected and fixed in formalin, whereas tumors were cut in half
and one half was snap-frozen in liquid nitrogen subsequent to
RNA extraction whereas the other half was embedded in OCT
compound (x) and frozen at 220uC. 10 mm thick cryostat sections
were cut from the blocks and mount on superfrost slides which
were then subjected to immunofluorescence staining.
Immunofluorescence Staining of Tumor Sections
Immunofluorescence studies were performed as described
before [40,113,114]. Frozen tissue sections of xenografts were
fixed in ice cold acetone for 10 minutes. After blocking with 1%
BSA, 16 PBS, sections were incubated with primary antibody
against Peg3, Bmp2k or Zc3hav1 for 1 hour at room temperature.
Sections were then probed with goat anti-rabbit IgG Alexa FluorH
594 (Invitrogen). Washed sections were mounted with Prolong
Gold (Invitrogen) and visualized using a Leica DM5500B
microscope with Advanced Fluorescence 1.8 software (Leica
Microsystems, Inc.). All the images were analyzed with Adobe
Photoshop CS3 (Adobe Systems, San Jose, CA). Three-dimen-
sional surface plots were generated utilizing ImageJ software.
Isolation of Mouse Mammary Fibroblasts and Co-culture
Experiments
Female wild type C57BL/6J mice were used to isolate primary
mammary fibroblasts. Briefly, the fourth and fifth mammary
glands were removed aseptically and minced with surgical blades.
All the fragments were collected and diluted in 10 ml of digestion
media (DMEM, 2 mg/ml collagenase type I, 50 mg/ml gentami-
cin) and incubated in a shaker (2 hours at 37uC) with gentle
shaking. The solution was then centrifuged 10 minutes at
1000 rpm in order to eliminate floating fat cells. The obtained
pellet was washed twice in 10 ml growth media (DMEM, 10%
fetal bovine serum, pen/strep) containing fungizone. The cell
pellet was then disaggregated by gently pipetting up and down
with a 1 ml pipette tip. The cell resuspension was plated in 6-cm
2
dishes coated with gelatin and cultured in growth media
containing fungizone. After a week, the fibroblast culture was
switched to growth media and passaged accordingly.
For co-culture experiments, sub-confluent primary cultures of
mouse mammary fibroblasts were seeded with 1.0–1.5610
5 MDA-
231 mammary carcinoma cells. The co-cultures were allowed to
incubate for several hours for engagement of the fibroblast feeder
layer. Co-cultures were then serum starved overnight whereupon
chronic decorin treatment (100 nM decorin protein core) began
for a total of three days. Arrival of the end-point resulted in lysing
of the co-cultures in either a sufficient volume of RIPA buffer for
immunoblot analyses or TRIzol (Invitrogen) to isolate total RNA
and subsequent cDNA synthesis for gene expression analysis.
Real-Time Gene Expression Verification and Analysis
Independent authentication of gene expression analysis was
carried out by quantitative real-time polymerase chain reaction
(qPCR) to confirm gene changes. Briefly, for in vivo samples, MDA-
231 tumor xenografts tissue samples treated systemically with
decorin protein core (10 mg/kg) for 23 days were snap-frozen with
liquid nitrogen and homogenized with a mortar and pestle prior to
solubilization in 2 ml of TRIzol (Invitrogen, Grand Island, NY), or
alternatively, at the end point of the co-cultures (following three
days of chronic 100 nM decorin protein core exposure), 6-cm
2
dishes were lysed in 2 ml of TRIzol. Subsequently, isolated total
RNA (1 mg) was annealed with oligo(dT) primers, and cDNA was
synthesized utilizing the SuperScript Reverse Transcriptase II
(Invitrogen) according to the manufacturer’s instructions. Gene-
specific primer sets for Mus musculus mRNA (refer to Table S1 and
Table 1) were rigorously designed and verified prior to use in
qPCR. Target genes and the endogenous housekeeping gene, Actb,
amplicons were amplified in independent reactions using Brilliant
SYBR Green Master Mix II (Agilent Technologies, Cedar Creek,
TX). All samples were run in triplicate with quadruplicate plate
replicates on the Roche LightCycler 480-II Real Time PCR
platform (Roche, Madison, Wisconsin) and the cycle number (Ct)
was obtained for each independent amplicon reaction followed
fold change determination via the Comparative Ct method for
gene expression data analysis. Delta Ct (DCt) values are
representative of normalized gene expression levels with respect
to Actb. The delta delta Ct (DDCt) values represent experimental
cDNA (samples treated with decorin protein core) minus the
corresponding DCt of the calibrator sample (control samples).
Finally, the reported fold change represents an average of the fold
changes as calculated using the double DCt method (2
2DDCt).
Supporting Information
Figure S1 SDS-PAGE gel demonstrating the purity of
the decorin protein core preparation. SDS-PAGE gel
representing increasing amounts (0.5, 1, 2, and 5 mg) of decorin
protein core run in parallel with increasing amounts of BSA (2 and
5 mg), as indicated. The gel was subsequently stained with colloidal
Coomassie blue for highly sensitive detection (as low as 5 ng) of
any co-purifying bands in the decorin protein core preparation
used. The left lane indicates the migration of the molecular mass
(kDa) of standard proteins.
(TIF)
Figure S2 Systemic administration of decorin protein
core induces Zc3hav1 levels in MDA-231(GFP+) xeno-
grafts. A–B: Immunofluorescence images of control and decorin-
treated MDA-231(GFP+) tumor xenografts, reacted with an anti-
Zc3hav1 antibody. Mice bearing MDA-231(GFP+) tumor xeno-
grafts were treated with intraperitoneal injection of human
recombinant decorin core protein (10 mg/kg) every other day
for 23 days. All the micrographs were taken using the same
exposure and gain. Three-dimensional surface plots, on the right
of each panel, were generated utilizing ImageJ software and
represent Zc3hav1 expression which directly corresponds to the
signal intensity obtained by the immunofluorescence. The scale
bars for signal intensity are included on the right of each surface
plot. Bar=20 mm.
(TIF)
Table S1 Primer pairs specific for the exclusive detec-
tion of Mus Musculus genes with accompanying gene
symbol and NCBI accession number.
(DOCX)
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